Imagen de Portada

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Jialing Wang, Wenjun Meng
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
por: Landon Long Chan, et al.
Publicado: (2025)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
por: Xiaosong Li, et al.
Publicado: (2024)

Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
por: Yinghan Chen, et al.
Publicado: (2026)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
por: Naohiro Yasuura, et al.
Publicado: (2024)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
por: Tsutomu Nishida, et al.
Publicado: (2026)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC
por: Beom Kyung Kim
Publicado: (2025)

Letter: Identifying the Best Model for Predicting Post‐SVR HCC
por: Hidenori Toyoda
Publicado: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
por: Shuai Xia, et al.
Publicado: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
por: Cong Dai, et al.
Publicado: (2024)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
por: Subin Heo, et al.
Publicado: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
por: Sai Kiran Kuchana, et al.
Publicado: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
por: Isabel Carbery, et al.
Publicado: (2024)

Letter: Enhancing HCC Surveillance– GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety
por: Ibrahima Gueye
Publicado: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
por: Christian Labenz, et al.
Publicado: (2026)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
por: Dong Hyun Kim, et al.
Publicado: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
por: Sifu Yang
Publicado: (2025)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
por: Wenjun Meng, et al.
Publicado: (2024)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
por: Abdulrahman Ismaiel
Publicado: (2026)

Editorial: HBV Integration: A Possible Key Driver in the Course of Patients With Chronic HBV Infection Under Viral Suppression
por: Hidenori Toyoda
Publicado: (2025)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
por: Gamal Shiha, et al.
Publicado: (2025)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
por: Qin Ning, et al.
Publicado: (2025)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
por: Subin Heo, et al.
Publicado: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
por: Jiwon Yang, et al.
Publicado: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
por: Bernardo de Faria Moraes, et al.
Publicado: (2026)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
por: Jia‐Ling Wu, et al.
Publicado: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
por: Dong Hyun Kim, et al.
Publicado: (2025)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
por: Xinli Chen, et al.
Publicado: (2024)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
por: Yuanyan Sun, et al.
Publicado: (2026)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
por: Jiong Yu, et al.
Publicado: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
por: You‐Jian Xu, et al.
Publicado: (2024)

Letter: Optimising Targeted Next‐Generation Sequencing for Intestinal Tuberculosis Diagnosis—Methodological Considerations
por: Haleema Rahman
Publicado: (2025)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
por: Joëlle St‐Pierre, et al.
Publicado: (2026)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
por: Rui Zhang, et al.
Publicado: (2024)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
por: Kuo‐Cheng Wu, et al.
Publicado: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
por: Jianhui Zhao, et al.
Publicado: (2024)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
por: Ming Liu, et al.
Publicado: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
por: Jia‐Yong Su, et al.
Publicado: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
por: Yash Hegde, et al.
Publicado: (2026)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Publicado: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
por: Isabella Lurje, et al.
Publicado: (2025)